When the BioPlan survey separately asked respondents about the percentage of their production that they expect to outsource
in five years (i.e., by 2018), similar trends hold true. Future outsourcing of plant-and insect-cell systems appears to be
rising while outsourcing of traditional systems remains steady, suggesting a relatively stable production environment. The
preliminary data from 2013 show:
Mammalian cell-culture systems: 62.5% of respondents in 2013 (58.2% in 2012 and 63.5% in 2011) indicated they expect to outsource at least some of their
production in the next five years.
Microbial fermentation: In 2013, 68.2% of respondents (72.2% in 2012 and 59.6% in 2011) plan to outsource some production by 2018.
Yeast systems: 40% of respondents in 2013 (45% in 2012 and 52.2% in 2011) believe that at least some of their production will be outsourced
in the next five years.
Insect-cell systems: 42.9% of respondents in 2013 (26.7% in 2012) plan to outsource some production by 2018.
Plant-cells systems: 40% of respondents in 2013 (25% in 2012) expect to outsource some production in the next five years.
Capacity utilization trends
Although outsourcing of traditional expression systems has remained fairly steady in BioPlan's preliminary data, capacity
utilization may be trending upward after several years of decline. Capacity utilization is important for ensuring productivity
and cost-effective operations. Lower utilization equates to more idle capacity. A certain amount of flexible capacity is needed
to ensure availability during stress operations. Also, CMOs require open capacity to ensure they are not turning away potential
clients. Conversely, too little capacity can lead to production and delivery problems. Ten years ago, capacity utilization
was a more prominent issue. Today, increased yield of titers, improved bioproduction modeling, the use of disposables, and
better planning have lifted most capacity problems.
Manufacturers, however, continue to work toward optimized upstream and downstream process operations. In upstream bioprocessing,
mammalian cell-culture capacity in 2013 is averaging 65.4% of total capacity, which would be its highest level since 2006,
according to BioPlan's preliminary data. Capacity use has stabilized at roughly 62% during the past six years after declining
from 76.4% in 2004. Meanwhile, the rebound is even greater for microbial fermentation. After decreasing steadily from 71%
in 2004 to 49.5% in 2012, capacity utilization appears to have increased to 62% this year. For yeast culture, the initial
data showing 48.4% capacity utilization represent an uptick from a 2012 level of 35.7%, but is more in keeping with prior
years, which ranged from 44.9% to 46.8% between 2006 and 2011. Capacity utilization for plant- and insect-cell systems remains
steady comparative to 2012, but noting again the potential for "noisy" data due to the small number of respondents using these
For essentially all expression systems, there appears to be underutilized capacity, which is preferable for companies when
compared to a shortage of capacity. Despite utilization percentages having decreased in recent years, new capacity and higher
yields were established during this period, so overall biomanufacturing levels (i.e., output) have risen considerably.
Despite steady utilization rates in insect- and plant-cell expression systems, outsourcing appears to be rising. For traditional
mammalian and microbial expression systems, capacity utilization rates are trending upward while outsourcing has remained
flatter. On the surface, capacity utilization and outsourcing would appear to be interconnected-when capacity is scarce, outsourcing
becomes an option. For many bioprocessing technologies, however, selection factors may be more associated with the availability
of technical competence among outsourcing suppliers and CMOs rather than simply access to available production capacity.
Eric Langer is president of BioPlan Associates, tel. 301.921.5979, email@example.com
, and a periodic contributor to Outsourcing Outlook.